Last edition
News about
Johnson & Johnson Secures FDA Priority Review for Imaavy in Rare Blood Disorder
Johnson & Johnson moves closer to delivering a first-in-class treatment for Warm Autoimmune Haemolytic Anaemia with FDA Priority Review for Imaavy.
Novartis Secures EC Approval for First Oral Targeted CSU Drug Rhapsido
Novartis introduces Rhapsido in Europe, offering a first-of-its-kind oral targeted therapy for patients with chronic spontaneous urticaria.
AstraZeneca Wins US Approval for Self-Administered Saphnelo Pen for Lupus Treatment
AstraZeneca launches a self-injectable version of Saphnelo, offering lupus patients a more convenient treatment option with proven efficacy and safety.
TESARO Provides Update on AnaptysBio Litigation
TESARO Inc., part of GlaxoSmithKline plc, provides an update on litigation with AnaptysBio Inc., reaffirming its declaratory judgment claim and intent to pursue the case at trial.
US FDA Approves CAPLYTA (lumateperone) sNDA for Schizophrenia Relapse Reduction
US Food and Drug Administration (FDA) approves CAPLYTA (lumateperone) sNDA for schizophrenia, showing a 63 percent reduction in relapse risk and 84 percent relapse-free patients over six months, with strong long-term safety and stability data.
Xcovery Partners with EVERSANA to Launch Ensacove in US
Xcovery Holdings Inc. partners with EVERSANA to commercialize Ensacove in the U.S., leveraging end-to-end services including market access, medical and commercial support to expand lung cancer treatment availability.
Eli Lilly and Company to Acquire Ajax Therapeutics to Expand Blood Cancer Pipeline
Eli Lilly and Company to acquire Ajax Therapeutics, advancing its blood cancer pipeline with AJ1-11095, a Phase 1 JAK2 inhibitor targeting myelofibrosis and polycythemia vera, with potential for improved disease control.
Nova Polymers Inc. Launches Pure Exterior Substrate for ADA Signage
Nova Polymers Inc. launches Novacryl EX, an exterior-grade photopolymer substrate engineered for durable, ADA-compliant signage, offering high moisture and humidity resistance for long-lasting performance and adherence to regulatory standards.
Cellenkos Inc. Wins US FDA Clearance for Phase 2 Trial of CK0801 in Aplastic Anemia
Cellenkos Inc. receives US Food and Drug Administration (FDA) clearance to initiate a Phase 2 multicentre trial of CK0801, evaluating safety and efficacy of cord blood-derived Tregs in transfusion-dependent aplastic anemia patients.
National Institute for Health and Care Research launches a nationwide collaboration to accelerate Parkinson’s research, bringing together academia, NHS and charities to drive faster development of treatments and diagnostics.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy